Efalizumab in routine use: a clinical experience.

about

Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents.Infectious complications associated with monoclonal antibodies and related small molecules Effect of Efalizumab on neutrophil and monocyte functions in patients with psoriasis.

P2860

Q34112840-B7E5BDD8-DABC-451A-9971-D9710182ECD5 Q37156636-5DFBFD34-E085-489B-AE8D-8150415660D0 Q46545360-FDF31158-03DF-48D1-A4B6-B2E430190192

P2860

Efalizumab in routine use: a clinical experience.

Item

http://www.wikidata.org/entity/Q44124198

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh

2007年學術文章

@zh-hant

name

Efalizumab in routine use: a clinical experience.

@en

Efalizumab in routine use: a clinical experience.

@nl

type

Item

label

Efalizumab in routine use: a clinical experience.

@en

Efalizumab in routine use: a clinical experience.

@nl

prefLabel

Efalizumab in routine use: a clinical experience.

@en

Efalizumab in routine use: a clinical experience.

@nl

P1476

Efalizumab in routine use: a clinical experience.

@en

P2093

F Karlhofer

http://www.w3.org/2001/XMLSchema#string

G Stingl

http://www.w3.org/2001/XMLSchema#string

N Selenko-Gebauer

http://www.w3.org/2001/XMLSchema#string

P2860

Efalizumab: a review of events reported during clinical trials and side effects.

Comparative tolerability of systemic treatments for plaque-type psoriasis.

T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): mechanisms of action.

Psoriasis causes as much disability as other major medical diseases.

Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study.

Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study.

CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial.

Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.

Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial.

Randomized Clinical Trials for Psoriasis 1977–2000: The EDEN Survey

P304

1-6

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2133.2007.07762.X

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

156 Suppl 2

http://www.w3.org/2001/XMLSchema#string

P577

2007-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17371316

http://www.w3.org/2001/XMLSchema#string

Efalizumab in routine use: a clinical experience.

about

P2860

P2860

Efalizumab in routine use: a clinical experience.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P698